<DOC>
	<DOCNO>NCT01220817</DOCNO>
	<brief_summary>When give men recurrent prostate cancer , investigator hypothesize POMx effective slow rise PSA measure PSA double time men follow initial therapy prostate cancer . Further , investigator believe POMx show safe well tolerate .</brief_summary>
	<brief_title>Safety Efficacy POMx Capsules Men With Recurrent Prostate Cancer : An 18-Month Study</brief_title>
	<detailed_description>The study 18-month , prospective , multi-center , double-blind , dose find study subject undergone definitive treatment ( surgery , cryotherapy , radiation therapy brachytherapy ) primary prostate tumor document rise PSA minimum 3 time point least 1 month apart , high reference value note within 1 year study entry .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Subject histologically cytologically confirm adenocarcinoma prostate . Subject undergone definitive treatment ( surgery , surgery radiation therapy , cryotherapy , radiation therapy brachytherapy ) primary prostate tumor . Subject rise PSA postprostatectomy may consider radiation alternative . If subject decline radiation , may consider eligible setting . Subject rise PSA minimum 3 time point least 1 month apart , high reference value note within 1 year study entry define : Absolute level PSA &gt; 0.4 ng/mL follow surgery . Absolute level PSA &gt; 1.5 ng/mL follow radiation cryotherapy . Absolute level PSA &gt; 0.4 ng/mL subject treat multiple treatment modality ( e.g. , surgery + radiation , radiation + cryotherapy , etc. ) . Absolute level PSA &gt; nadir + 2 follow neoadjuvant hormonal therapy along external beam radiation . Interim PSA value immediate prestudy interval may demonstrate `` fluctuation '' include decline ; however , study baseline PSA must show rise within prestudy 1 year period . Study baseline PSAs must determine within 4 week study entry . First postoperative PSA permit detectable . Subject &gt; 18 year age . Subject life expectancy great 6 month . Subject ECOG performance status 0 , 1 2 Subject testosterone level &gt; 150 ng/mL screening . Subjects normal organ marrow function define : leukocyte &gt; 3,000/mcL absolute neutrophil count &gt; 1,500/mcL platelet &gt; 100,000/mcL total bilirubin within normal limit except Gilberts AST ( SGOT ) /ALT ( SGPT ) &gt; 2.5 X upper limit normal creatinine &gt; 2.5 upper limit normal testosterone level &gt; 150 ng/mL Subject agree abstain commercially available pomegranate product participate study . Subject 's use dietary/herbal supplement ( e.g . saw palmetto , selenium , etc ) stable least 2 month prior screen subject agrees stop change dose participate study . Subject sign write informed consent document agree comply requirement study . Subject known radiographic evidence metastatic disease , except presence positive lymph node surgical pathology . Subject receive therapy modulate testosterone level ( e.g. , androgen ablative/antiandrogen therapy , herbal therapy contain estrogen ) minimum 1 year prior study . Subject prior concomitant treatment experimental drug , high dose steroid , cancer treatment within 4 week prior first dose study product . Subject consume two 8 ounce glass pomegranate juice per week past 2 month . Subject know allergy pomegranate juice ellagic acid . Subject uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>prostate</keyword>
	<keyword>cancer</keyword>
	<keyword>psa</keyword>
	<keyword>psadt</keyword>
	<keyword>pomegranate</keyword>
	<keyword>POMx</keyword>
</DOC>